Medicine and Dentistry
Heart Failure
95%
Doxorubicin
71%
Phospholamban
71%
Cardiomyopathy
71%
Cardiotoxicity
71%
Personalized Medicine
71%
Interleukin 17
71%
Disease Severity
71%
Serositis
71%
Disease
59%
Heart Disease
35%
Engineered Heart Tissue
28%
Symptom
23%
In Vitro
19%
Resveratrol
14%
5 Amino 4 Imidazolecarboxamide
14%
Ribonucleotide
14%
Left Ventricle
14%
Pathophysiology
12%
Gene Silencing
11%
Isotopes of Calcium
11%
Protein Aggregation
11%
Biological Marker
11%
Signal Transduction
11%
Gene Mutation
11%
Phenotype
11%
Troponin
7%
Cancer Therapy
7%
Biopsy Technique
7%
Cellular Senescence
7%
Upregulation
7%
Cardiac Muscle Cell
7%
Inflammatory Disorder
5%
Chemokine
5%
Brain Natriuretic Peptide
5%
New York Heart Association Class
5%
Interleukin 6
5%
Amino Terminal Sequence
5%
Deterioration
5%
Leukocyte Activation
5%
FGF21
5%
Heart Function
5%
Knock Out
5%
Immune Response
5%
Tumor Necrosis Factor Receptor
5%
Cytokine
5%
Cardiac Fibrosis
5%
Interleukin 1 Receptor Blocking Agent
5%
Enzyme Linked Immunosorbent Assay
5%
Lymphocyte
5%
Keyphrases
Phospholamban
71%
Senescence
71%
Doxorubicin-induced Cardiotoxicity
71%
Inherited Cardiomyopathy
71%
Precision Medicine
71%
Engineered Heart Tissue
40%
Doxorubicin
40%
Senomorphics
40%
Genetic Heart Disease
23%
Treatment Strategy
23%
Heart Failure
23%
Cardiotoxicity
20%
Left Ventricle
20%
Resveratrol
20%
Clinically Significant
20%
Senescence-associated
20%
Carboxamide
20%
Ribonucleotides
20%
5-Aminoimidazoles
20%
Derived Material
11%
Disease Modifier
11%
Metabolic Dysfunction
11%
Disease-related
11%
Signal Transduction
11%
Biological Pathways
11%
Cardiomyopathy
11%
Novel Biomarkers
11%
Neurohormonal
11%
One-size-fits-all
11%
Gene Silencing
11%
Pathophysiological Mechanisms
11%
Therapeutic Target
11%
Metabolic Proteins
11%
Deep Phenotyping
11%
Patient-derived
11%
Poor Prognosis
11%
Genetic mutation
11%
Protein Aggregation
11%
In Vitro Disease Modeling
11%
Heart Disease
11%
Novel Treatments
11%
Dysregulation
11%
Calcium Dysregulation
11%
Dilatation
10%
Senescence Markers
10%
Patient Treatment
10%
Pathophysiology
10%
Treatment Regimen
10%
Molecular Mechanism
10%
Troponin Release
10%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Disease
71%
Disease Severity
71%
Phospholamban
71%
Interleukin 17
71%
Cardiomyopathy
71%
Inflammation
71%
Doxorubicin
71%
Cardiotoxicity
71%
Heart Disease
42%
Symptom
28%
Biological Marker
14%
Ribonucleotide
14%
Resveratrol
14%
Syndrome
14%
5 Amino 4 Imidazolecarboxamide
14%
Pathophysiology
12%
Malignant Neoplasm
7%
Troponin
7%
Inflammatory Disease
5%
Cytokine
5%
Chemokine
5%
Brain Natriuretic Peptide
5%
Enzyme-Linked Immunosorbent Assay
5%
Interleukin 6
5%
Deterioration
5%
Interleukin 1 Receptor Blocking Agent
5%
Tumor Necrosis Factor Receptor
5%
Fibroblast Growth Factor 21
5%
Fibrosis
5%
